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The safety of radiofrequency ablation of the great
saphenous vein in patients with previous venous
thrombosis
Alessandra Puggioni, MD, Natalie Marks, MD, RVT, Anil Hingorani, MD, Alexander Shiferson, DO,
Saadi Alhalbouni, MD, and Enrico Ascher, MD, Brooklyn, NY
Background: The safety of radiofrequency ablation (RFA) of the great saphenous vein (GSV) in patients with previous
history of deep venous thrombosis (DVT) has not been determined.
Methods: From April 2003 to June 2006, 274 patients (68% women; mean age, 60 years  15 years) underwent 293
consecutive RFA procedures. In the first 15 months, the temperature probe was maintained at 85°C, with a pullback rate
of 2 cm/min (85 limbs, 30%); we subsequently changed the protocol to 90°C and a pullback rate of 2 to 3 cm/min (205
limbs, 70%). We identified 29 patients (10%) with a history of DVT or duplex scan evidence of post-thrombotic venous
disease; these were compared with the remaining 264 (90%). Postprocedural acute thrombotic (AT) events were analyzed.
By the CEAP classification, 204 limbs (70%) were C2 to C4, and 89 (30%) were C5 to C6. Thirty-seven patients (13%) had
a history of superficial thrombophlebitis (SVT). Proximal mean GSV diameter was 0.95  0.29 cm (range, 0.4-2.3 cm).
Concomitant procedures included avulsion phlebectomy in 88 limbs (30%) and perforator vein surgery in 4 (1%).
Results: AT events after RFA were detected in 38 limbs (13%), including thrombus protrusion into the sapheno-femoral
junction (SFJ) in 24 (8%), common femoral vein in 7 (2.5%), and calf vein DVT in 7 (2.5%). Overall incidence of AT
events in limbs with and without evidence of previous DVT was 7% (2 of 29) and 14% (36 of 264), respectively (P .36).
Variables significantly associated with AT events were previous SVT (10 of 37 [27%] vs 28 of 256 [11%], P  .01), a
larger GSV diameter (mean 1.1  .39 vs 0.93  0.27, P < .01), and first protocol (catheter temperature of 85°C with a
slower pullback rate in 18 of 88 [20%] vs 20 of 205 [9.7%], P  .02). Concomitant venous operations were associated
with an increase in AT events (23% vs 9%; P< .002). By multivariate analysis, larger proximal GSV diameter and previous
SVT remained independently statistically significant (P  .049 and P  .0135, respectively). All AT patients were
successfully treated with standard anticoagulation. No pulmonary emboli occurred.
Conclusion: RFA of the GSV in patients with previous venous thromboembolic events is safe and should be offered as an
alternative to surgical procedures. These data demonstrate that AT events increase when larger-diameter GSVs are
treated. (J Vasc Surg 2009;49:1248-55.)Great saphenous vein (GSV) reflux is important in the
development of signs and symptoms of chronic venous
insufficiency.1 Radiofrequency ablation (RFA) of the GSV
was introduced as a minimally invasive alternative to strip-
ping, with the aim of interrupting venous flow through the
incompetent GSV. This technique is relatively simple to
perform and is associated with high patient satisfaction and
an earlier return to work compared with traditional strip-
ping.2
Although the main mechanism of action of RFA is vein
spasm and collagen shrinkage by delivery of thermal en-
ergy, thrombus formation within the GSV has been de-
scribed.3 Deep venous thrombosis (DVT) after RFA of the
GSV has been reported with a variable incidence of 0% to
16%.2-7 Many authors consider a history of venous throm-
boembolic events is a risk factor for development of DVT
after endovenous GSV ablation because this group of pa-
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1248tients is generally excluded from studies.2,8-10 The aim of
this study was to evaluate the safety of RFA of the GSV in
patients with previous venous thrombotic events.
METHODS
Patients. During the 38 months from April 2003 to
June 2006, we performed 293 consecutive RFA procedures
on the GSV in 274 patients who were available for 1 week
of follow-up. The Institutional Review Board approved the
retrospective chart review of patients who underwent GSV
ablation. During the same time period, we also performed
62 GSV stripping procedures for the treatment of symp-
tomatic GSV reflux. Criteria for performing stripping vs
RFA included known allergic reactions to local anesthetics,
presence of a pacemaker or a defibrillator, inability to
cannulate the GSV due to excessive tortuosity or a post-
phlebitic vein, early recanalization after RFA, and the pa-
tient’s preference.
All limbs were classified according to the CEAP11
classification: 204 limbs (70%) were C2 to C4 and 89 (30%)
were C5 to C6 (healed or active venous ulcers). Indication
for treatment of GSV reflux was any clinical stage of symp-
tomatic venous insufficiency that did not improve after a
trial of compressive therapy. Patients with a well-known
history of lower extremity venous thromboembolic events
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for DVT, with medical records available to document the
event, (2) by history had a DVT that was treated by
standard anticoagulation, or a DVT/pulmonary embolism
(PE), or a DVT necessitating an inferior vena cava (IVC)
filter, or (3) had a history of venous clot and duplex
evidence of post-thrombotic changes in the examined deep
veins.
Demographics, procedural data, and duplex scan find-
ings were retrospectively collected and analyzed.
Duplex study. Preoperative and postoperative duplex
scanswere performed inour accreditednoninvasive laboratory
by registered vascular technologists using high-resolution
color duplex scanners (HDI 5000 with Sono-CT option,
Philips, Bothell, Wash). Veins were examined in the trans-
verse and longitudinal views. All examinations were re-
corded on videotape and interpreted by an attending vas-
cular surgeon. Interrogation of the superficial and deep
venous systems included the GSV, small saphenous vein
(SSV), common femoral vein (CFV), femoral vein, popli-
teal vein, and calf veins.
Venous segments were considered incompetent if re-
versed flow lasted 0.5 seconds in the standing position
after manual compression and release. Standardized criteria
for the diagnosis of acute DVT included diminished or
absent color Doppler signals with respiration or augmenta-
tion maneuvers, echogenic signals within the vein lumen
either partially or completely occluding the vessel, inability
to compress the vein by pressure on the transducer, and
dilated veins where thrombus was suspected.12
Once a DVT diagnosis was made, all vein segments
involved were recorded. Post-thrombotic changes in exam-
ined veins were identified as obstructed or narrowed veins
with thickened wall and reduced compressibility, intralumi-
nal webs, hyperechoic material, multiple channels, and
partly destroyed, thickened valves, as well as increased
venous collaterals.13,14 Perforator incompetence was not
routinely investigated.
Technique. RFA of theGSVwas performed according
to the guidelines recommended by the manufacturer
(VNUS Medical Technologies Inc, San Jose, Calif). The
procedures were performed by three different vascular sur-
geons in collaboration with a physician/senior RVT
(N. M.) according to a standardized protocol. The GSV
was punctured under ultrasound guidance about the knee
level, and an introducer sheath was advanced over a J wire;
the RFA catheter was then positioned in the GSV, 1 cm
distal to the superficial epigastric vein.
Tumescent anesthesia (400 mL of normal saline mixed
with a 40 mL solution of 1% lidocaine, with 1:100,000
epinephrine and 5 mL of 7.5% sodium bicarbonate solu-
tion) was infiltrated around the target vein to obtain vein
wall apposition and to reduce heat dissipation to the
perivenous tissues. A continuous drip of heparinized solu-
tion (5000 U of heparin in 500 mL of normal saline) was
infused through the tip of the RFA catheter at a rate of
approximately 1 drop/s.During the first 12 months of the study period, these
procedures were performed in the hospital under general or
spinal anesthesia. Combined procedures included stab-
avulsion phlebectomies in 126 limbs (43%) and concomi-
tant perforator interruption in four patients (1%) with
long-standing nonhealing leg ulcers and perforators/GSV
reflux deemed fit for surgery.
In the last 16 months (167 limbs, 57%), the RFA was
changed to an outpatient, office-based procedure and was
performed without concomitant procedures and under lo-
cal and tumescent anesthesia only, without additional seda-
tion. The temperature probe was maintained at 85°C with
a pullback rate of 2 cm/min in the first 15 months of the
study period (85 limbs, 30%). We subsequently switched to
a temperature of 90°C with a pullback rate of 2 to 3
cm/min (205 limbs, 70%). A 6F catheter was used in 195
limbs and an 8F in 35 (data available on 231 limbs).
At the end of the procedure, all treated veins were
imaged to confirm complete GSV closure and rule out
extension of thrombus into the CFV. An ACE compressive
bandage (BD, Franklin, NJ) was then applied from toes to
groin to be maintained for the next 48 hours. Patients were
encouraged to walk as soon as possible, with no significant
limitations, and discharged home the same day.
We did not administer perioperative DVT prophylaxis
drugs. If patients were already receiving an anticoagulant
regimen, this was held for 5 days preoperatively and re-
sumed after the procedure. This was done to decrease the
risk that hematomas would develop after possible inadver-
tent vein perforations and at the catheter access site or at the
sites of tumescent anesthesia infiltration. Laboratory evalu-
ation of thrombophilia in patients with previous DVT was
not routine.
Follow-up. Postoperative duplex scanning and clini-
cal evaluation was routinely obtained at a mean of 5.8 1.8
days in all except eight patients, who were excluded from
the study. Patients were asked to return at 1 to 2 months
and 6 months, but compliance was limited by the charac-
teristics of this particular patient population (age, comor-
bidities, social-cultural background). Therefore, further
follow-up 1 year after the procedure was possible in 190
limbs (65%) at a mean of 53.5 66 days (median, 22 days).
Our follow-up protocol included duplex evaluation of
all superficial and deep vein segments of both lower extrem-
ities, including the tibial, peroneal, and calf muscle veins.
Obliterated GSVs appeared as noncompressible veins with
thickened wall and absence of venous flow, sometimes filled
with thrombus up to the sapheno-femoral junction (SFJ).
The study end point of acute thrombotic (AT) events was
defined as presence of DVT in any lower extremity segment
or a tail of thrombus extending proximally from the GSV
anywhere into the SFJ.
Management of AT events. In our early experience,
all patients with AT events received standard anticoagula-
tion therapy by unfractionated intravenous heparin or
enoxaparin, followed by warfarin at standard doses. Treat-
ment was continued until resolution of thrombus in case of
SFJ thrombi; all other patients with DVT were treated with
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ning of this series, patients who exhibited thrombus abut-
ting into the SFJ or CFV that appeared to be free floating
were managed by placement of an IVC filter. As we noticed
that all proximal thrombi after RFA resolved 2 weeks of
anticoagulation, we arbitrarily changed our management
policy and reserved caval filtration to patients who exhib-
ited thrombus persistence for 1 week or progression.4
Statistical analysis. Data were collected retrospec-
tively and entered into an electronic database. Patients with
a well-known history of lower extremity venous thrombo-
embolic events, or duplex scan evidence of it, were com-
pared with the rest of the series. Comparisons between two
groups of data were performed with the two-tailed Fisher
exact test or 2 test for categoric variables, as appropriate.
The Wilcoxon rank test was used for continuous variables.
A value of P  .05 was considered statistically significant.
RESULTS
Bilateral procedures were done in 19 of 274 patients at
different time intervals, comprising 152 left limbs (52%)
and 141 right (48%). There were 185 women (68%) and 89
men (32%), with a mean age of 60 15 years. All limbs had
documented GSV reflux. Deep venous reflux was observed
in 200 of 272 limbs (73%) available for examination and
was localized in the CFV in 112 (41%), the femoral vein in
37 (14%), and the popliteal vein in 161 (59%).
Evidence of a previous DVT was found in 29 of 293
limbs (10%), comprising ipsilateral in 22, contralateral in
six, and bilateral in one. Superficial thrombophlebitis
(SVT) had occurred in 37 (13%) and was ipsilateral in 34,
contralateral in two and bilateral in one.
The proximal GSV mean diameter was 0.95 0.29 cm
(range, 0.4-2.3 cm), and the mid-GSV mean diameter was
0.86  0.99 cm (range 0.2-2.03 cm). Veins treated with
the 6F catheter had proximal andmid-GSVmean diameters
of 0.97 0.02 cm and 0.87 0.07 cm, respectively; veins
treated with the 8F catheter had a proximal and mid-GSV
mean diameters of 0.92  0.05 cm and 0.9  0.18 cm,
respectively (P  .32 and P  .88, respectively).
Concomitant venous procedures were performed in 90
patients and included avulsion phlebectomy alone in 86
limbs (29), perforator vein surgery alone in 2 (0.7%) and
both, phlebectomy and perforator surgery, in 2 (0.7%);
these included three subfascial endoscopic perforator vein
procedures and one open perforator interruption.
Age, gender, clinical presentation, presence of preop-
erative deep vein reflux, catheter size, and temperature were
not significantly different between limbs with previous
DVT and the rest of the limbs (Table I). However, limbs
with previous DVT had also a higher incidence of previous
SVT (10 of 37 [27%] vs 19 of 256 [7%], P  .001) and a
smaller GSV diameter (0.84  0.06 vs 0.96  0.02, P 
.04). Concomitant venous procedures were performed
more often in patients without previous DVT (87 of 264
[33%] vs 3 of 29 [10%], P  .01).
The overall incidence of AT after RFA was 13% (38 of
293 limbs) and included thrombus protrusion into the SFJin 24 (8%), CFV thrombus in seven (2.5%), and calf muscle
veins thrombus in seven (2.5%). On univariate analysis a
number of factors reached statistical significance (Table II).
AT events occurred in 7% (2 of 29) of patients with previ-
ous DVT and in 14% (36 of 264) without previous DVT
(P  .36). These AT events were not identified on the
intraoperative completion duplex, but all were found on
duplex follow-up. No clinically evident PE or other signif-
icant postoperative complication occurred in this series.
More advanced clinical stages (combined classes 5 and 6 of
CEAP) was not a predictive factor for development of AT
events (15 of 38 [39%] vs 74 of 255 [29%], P  .19).
Concomitant venous operations were associated with a
significant increase in AT events (20 of 90 [22%] vs 18 of
203 [9%]; P  .01); more so after avulsion phlebectomies
(P .001). Concurrent stab avulsion of varicosities did not
influence anatomic location of AT events (P  .84). AT
events did not develop in the three patients with previous
DVT who underwent concomitant procedures.
Other variables significantly associated with AT events
were previous SVT (10/37 [27%] vs. 28/256 [11%], P 
.01), a larger GSV diameter (mean 1.1  0.39 vs 0.93 
0.27, P  .01), catheter temperature of 85°C, and slower
pullback rate of the first treatment protocol compared with
the second treatment protocol (18/88 [20%] vs 20/205
[9.7%], P .02). Catheter size (6F vs 8F) did not affect the
rate of AT events (15% vs 12%, P  .79).
On multivariate analysis, only two variables—larger
proximal GSV diameter and previous SVT—remained in-
dependently statistically significant (P  .049 and P 
.0135, respectively).
AT events were treated with standard anticoagulation.
Eight patients (21%) received an IVC filter, five were per-
manent, and three were temporary; of which two were
removed at 17 and 22 days, respectively.
Of the 38 patients with duplex evidence of AT events,
36 (95%) were compliant with follow-up and underwent at
least one further duplex scan after the initial diagnosis.
Complete resolution of thrombus was demonstrated in 30
of 36 cases (83%) at a mean of 15.5  18.2 days (range,
2-60 days), and partial resolution was evident in two (6%) at
5 and 13 days, respectively. In the remaining three patients,
thrombus appearance (2 in the calf muscle veins and 1 in
the CFV) did not improve within the first 2 months after
diagnosis; pain and edema developed in two during follow-
up, suggestive for post-thrombotic syndrome. Thrombus
resolved in the eight patients who had received an IVC
filter; in this group, the mean interval between detection of
AT events and resolution of thrombus was 14  7.5 days.
DISCUSSION
The operative treatment of symptomatic saphenous
vein insufficiency has evolved from surgical elimination of
the source of reflux—GSV stripping—to less invasive en-
dovenous therapies—RFA and endovenous laser ablation
(EVLA)—where the vein is left in place but excluded from
the venous circulation. The main advantages of these en-
dovenous techniques compared with stripping are reduced
study)
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return to work.2 At our institution, patients can chose
between RFA and stripping. No prospective studies have
compared RFA with EVLA, but retrospective studies5,15
show similar efficacy and safety profile. It should be noted,
however, that the advantages of endovenous procedures
over stripping have been limited to short-term results, not
long-term recurrence or future complications.
The prevalence of DVT after saphenous RFA is be-
lieved to be 0.2% to 1%.2,3,7 Some reports,4-6 including one
by our group,4 have described a significantly higher risk of
AT events of 8% to 16%. As expected, these reports have
been the subject of significant controversy.16-18
This is a retrospective, observational study that includes
our experience with GSV RFA during a 3-year period
(2003-2006). Our technique of performing RFA carefully
followed the recommendations of the manufacturer and
was observed by company representatives after publication
of our initial data. No significant flaws were observed, and
no improvements in techniques were deemed necessary.
Our incidence of AT events has decreased significantly
Table I. Comparison of demographic and clinical data of
264) previous deep venous thrombosis undergoing great s
Variable No.
Total limbs, No. (%) 293




CEAP clinical presentation, No. (%)
C2-C4 204
C5-C6 89
Previous SVT, No. (%)
No 256
Yes 37
Prox GSV diameter, mean  SD cmc











Catheter size, No. (%)e
6F 195
8F 35
Catheter temp/pullback, No. (%)f
85°C at 2 cm/min 88
90°C at 2-3 cm/min 205
CFV,Common femoral vein;DVT, deep venous thrombosis; FV, femoral vei
aValues of P  .05 are statistically significant.
bFor statistical purposes, limbs were calculated as patients.
cRange was 0.4 to 2.3 cm for both groups.
dA total of 272 limbs were available for examination of the deep vein system
eData were available for 230 limbs.
f85°C was used during the first treatment protocol (first 15 months of theover the years and with a change in protocol, thus indicat-ing that this adverse occurrence might have been partly
linked to the learning curve. The rate of AT events was
significantly higher in the first treatment protocol (85°C
and slower pullback rate) compared with the second pro-
tocol (90°C and faster pullback rate). It is also possible that
lower temperatures result in incomplete vein damage and
thrombus formation, whereas higher temperatures may
result in improved denaturation of the vein wall and endo-
thelial injury with ablation of the vein by shrinkage rather
than thrombus formation. In some other cases, close prox-
imity of the RFA catheter to the SFJ could have been
responsible for these thrombotic events.
Higher incidence of DVT in this series may also be
due to older age compared with patients in other reports,
as previously reported,4,5 and to the larger diameter of
treated GSVs. However, because we were unable to
demonstrate a statistically significant association be-
tween older age and AT events, we do not believe there
is currently enough evidence to just exclude these pa-
tients from a treatment they may significantly benefit
from. Rather, these patients should be encouraged to
limbs (274 patients) with (n  29) and without (n 
nous vein radiofrequency ablation
revious DVT No previous DVT Pa
29 (10) 264 (90)
63  2.6 59.8  0.9 .25
19 (65) 179 (68) .83
10 (35) 85 (32)
17 (58) 187 (71) .2
12 (42) 77 (29)
19 (65) 237 (90) .001
10 (35) 27 (10)
.84  0.25 0.96  0.29 .04
6 (21) 66 (27) .65
22 (79) 178 (73)
10 (35) 102 (38) .69
4 (14) 33 (13) .9
18 (62) 143 (54) .69
26 (90) 177 (67) .01
3 (10) 87 (33)
1 (3) 3 (1) .34
2 (7) 86 (33) .001
16 (80) 179 (85) .51
4 (20) 31 (15)
.3
6 (21) 82 (31)
23 (79) 182 (69)
, great saphenous vein; PV, popliteal vein; SVT, superficial vein thrombosis.





.ambulate immediately after the procedure, given ade-
study)
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vals.
We did not exclude large veins from RFA treatment.
The proximal GSV mean diameter was 0.95  0.29 cm
(range, 0.4-2.3 cm) andmid-GSVmean diameter was 0.86
0.99 cm (range, 0.2-2.03). Although several studies2,19 on
RFA initially excluded patients with a GSV diameter 1.2
cm, other authors did not consider large vein diameter an
exclusion criteria for study enrollment and successfully
treated them.9,10,20 Exclusion for saphenous vein diame-
ters1.2 was initially established as a conservative measure
but was later discontinued after reports of routinely suc-
cessful treatment. Detailed results of RFA for large veins
have been reported by Merchant et al21,22 on a 5-year,
multicenter study: of 39 veins with a diameter 1.2 cm
(range, 1.2-2.4 cm), occlusion rates were 97% at 1 week
and 93% at 6 months.
The increased rate of thrombus in the proximal GSV
Table II. Univariate analysis of risk factors for developme
radiofrequency ablation in 293 limbs
Variable Total No.
Limbs, No. (%) 293




CEAP presentation, No. (%)
C2-C4 204
C5-C6 89
Prox GSV diameter, mean  SD, cmc
Previous SVT, No. (%)
No 256
Yes 37
Previous DVT, No. (%)
No 264
Yes 29











Catheter size, No. (%)e
6F 195
8F 35
Mean catheter temp/pullback, No. (%)f
85°C at 2 cm/min 88
90°C at 2-3 cm/min 205
AT, Acute thrombotic; CFV, common femoral vein; DVT, deep venous th
superficial vein thrombosis.
aValues of P  .05 are significant.
bFor statistical purposes, limbs were calculated as patients.
cRange was 0.4 to 2.3 cm for both groups.
d272 limbs were available for examination of the deep vein system.
eData were available for 230 limbs.
f85°C was used during the first treatment protocol (first 15 months of theextending into the SFJ or CFV in cases of GSVs with largeproximal diameters might have been the result of inade-
quate delivery of tumescent anesthesia and insufficient
compression of the GSV at the SFJ. Incomplete wall appo-
sition may lead to excessive heating of blood and throm-
botic occlusion of the vein rather than collagen shrinkage.
Furthermore, inadequate heating of the vein wall due to
larger endothelial surfaces to be treated may increase colla-
gen exposure from underneath a denuded endothelium
and promote thrombus formation. To effectively occlude a
large-diameter vein, we now pay particular attention at
injecting additional tumescent infiltration in the perivenous
tissues until we obtain a “dry” vein.
Although extension of thrombus from the GSV into
the SFJ and formal DVTs both have been reported, few
authors actually described in detail their postoperative du-
plex scan protocol. We grouped all AT events because we
believed that they all could potentially be the source of PE
and should be treated accordingly. In their early experience
acute thrombotic events after great saphenous vein
AT events No AT events Pa
38 (13) 255 (87)
57.4  2.5 60.6  1 .19
29 (76) 169 (66) .27
9 (24) 86 (34)
23 (61) 181 (71) .19
15 (39) 74 (29)
1.1  0.39 0.93  0.27 .01
28 (74) 228 (89) .01
10 (26) 27 (11)
36 (95) 228 (89) .36
2 (5) 27 (11)
4 (36) 68 (33) .06
28 (74) 172 (67)
15 (39) 97 (38) .57
6 (16) 31 (12) .4
22 (58) 139 (55) .26
18 (47) 185 (73) .01
20 (53) 70 (27)
2 (5) 2 (1) .08
20 (53) 68 (27) .001
29 (88) 166 (84) .8
4 (12) 31 (16)
.02
18 (47) 70 (27)
20 (53) 185 (73)
sis; FV, femoral vein; GSV, great saphenous vein; PV, popliteal vein; SVT,
; 90°C was used for the second treatment protocol.nt of
rombowith endovenous ablation techniques, some authors have
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CFV to avert long-term anticoagulation,23 whereas others,
like our group, used IVC filtration.6 It is possible that the
natural history of an untreated SFJ thrombus is rapid fibri-
nolysis and thrombus resolution, or subclinical PE; unfor-
tunately, there are no prospective studies to support this
hypothesis.
A case of PE that was associated with a SFJ thrombus
extension and was not a true DVT has been reported.24 On
the other hand, in light of increased experience with the
procedure and given the small number of clinically signifi-
cant PE events reported in the literature, aggressive use of
systemic anticoagulation or IVC filtration is likely not nec-
essary inmost patients. As others have suggested,25 we have
more recently tended to treat SFJ thrombus extension with
antiplatelet therapy rather than anticoagulation until reso-
lution. In the other patients, any further proximal extension
of a DVT documented by repeat duplex ultrasound study is
a significant risk factor for PE12 and should be treated with
standard anticoagulation.
If we were only to report onCFVDVTs, our incidence of
this complication would have been 2%, slightly higher than
otherwise previously reported.8,22,26 Some may argue that
what we considered as a worrisome proximal extension of
GSV thrombus into the SFJ is an otherwise normal postoper-
ative finding and not to be treated or mentioned. Duplex
ultrasound imaging is certainly considered a reliable, repro-
ducible, and validated tool for diagnosing venous system
abnormalities; but it is important to point out how these
endovenous techniques are relatively new techniques. There-
fore, duplex findings after these procedures still need to be
classified and correlated with clinical outcomes.
Furthermore, occurrence of PE after RFA without a
detectable source of embolus at postoperative duplex scans
has been reported.27,28 We do not think that enough data
are available to absolutely exclude proximal extension of
GSV thrombus as a potential source of PE. Risk of PE after
endovenous GSV ablation is extremely low, but is not
exactly nil; several reports have described this serious com-
plication.22,24,26-30 Some patients have died: at least four
deaths after endovenous GSV ablation procedures are
posted on the Manufacturer & User Facility Device Expe-
rience (MAUDE) database maintained by the United
States Food and Drug Administration.28 It is unclear from
the descriptions of some studies whether extensions of
thrombus from the SFJ or true DVTs caused the PE.
The mechanism of proximal thrombus extension after
RFA is unclear. Thermal or mechanical endothelial damage
caused by the catheter itself might lead to thrombus forma-
tion at the SFJ in the postoperative period. Earlier reports31
described prophylactic ligation of the SFJ and tributaries as
a routine step to be performed along with RFA to avert
thrombus propagation into the CFV and to deal with the
risk of recanalization. With increased experience, this ma-
neuver has proved unnecessary because it did not alter
outcome for thromboembolic events.32 With the aim to
determine the clinical value of adjunctive proximal vein
ligation, Gradman30 created a survey for physicians per-forming endovenous GSV ablation procedures. Of 21,965
GSV obliteration procedures done by 22 practitioners, two
cases of PE (0.009%) and 34 of DVT (0.15%) were re-
ported. Of the 34 patients withDVT, at least 11 had duplex
evidence of thrombus extension into the CFV that was
asymptomatic and five had a calf muscle veins DVT. No
difference was noted between ligated and nonligated GSVs
in DVT occurrence.
Although a history of DVT is generally considered a
contraindication for endovenous ablation procedures, we
were unable to identify a study that directly addressed the
question whether RFA is safe in this group of patients. In a
review of literature, we found that main etiology of CVI (E
of CEAP classification) was secondary to a previous DVT
(Es) only in about 2% in RFA series5; more often, the cause
of chronic venous insufficiency was not reported. In the
Endovenous Radiofrequency Obliteration Versus Ligation
and Stripping (EVOLVeS) study,2 as well as other stud-
ies,8,9,10 an episode of previous DVT was one of the main
exclusion criteria for endovenous GSV ablation. Therefore,
the question remained open and prompted us to perform
this study.
To date, there is no reliable test and there are no
definitive criteria able to quantify deep venous obstruction.
Ascending phlebography can provide valuable information
on the patency of the deep system; however, the test is
invasive, is associated with a number of risks—including
DVT—and is mainly indicated in cases of planned deep
venous reconstructions. Duplex scan is rather performed if
only superficial venous surgery is being considered.
The traditional admonition against removal of the GSV
in post-thrombotic limbs has been re-examined by Raju et
al.33 Saphenectomy was clinically well tolerated in limbs
with or without deep venous obstruction, and no difference
in outcome was noted as measured by objective tests for
obstruction. Improvement in reflux and calf venous pump
function was largely similar. Saphenous ablation may ben-
efit patients with post-thrombotic syndrome with mixed
deep obstruction or superficial reflux and should not be
denied to this group of patients.
In a study byNeglén et al,34 99 limbs with concomitant
superficial reflux and deep venous obstruction (41% with
previous DVT) were treated by combined saphenous abla-
tion (27 by RFA) and iliac stent placement. Early DVT
occurred in only one patient in the contralateral iliofemoral
vein 27 days after the intervention. It is unclear whether this
was primary or post-thrombotic venous disease.
To our knowledge, only one report, by our group,4 has
analyzed risk factors for AT events after RFA techniques,
probably due to the low incidence of this complication in
most of the other series. After 73 RFA procedures, no
difference was found between the occurrence of DVT in
patients who underwent a combined procedure (RFA and
varicose vein excision) compared with patients who under-
went GSV RFA alone (P  .7).
Two separate reports on combined GSV EVLA and
phlebectomy in the treatment of varicose veins found a low
DVT rate of 0% and 0.13%, respectively.35,36 In a recent
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limbs,24 however, EVLA alone in 308 limbs (69.5%) and
combined with phlebectomy or perforator ligation in 135
limbs (30.5%) had an overall 7.9% incidence of AT events
(0.7% true DVTs and 7.2% SFJ thrombus extensions). The
true DVT rate was 2.2% for combined EVLA/venous
operations and 0% for isolated EVLA (P .028); the rate of
SFJ thrombus extension was 5.9% for combined EVLA/
venous operations vs 7.8% for isolated EVLA (P  .554).
The rate of AT events after EVLA and their higher inci-
dence after concomitant venous procedures are in agree-
ment with our findings.
One can speculate that the increased incidence of AT
events after RFA and concomitant venous operations may
be attributed to prolonged immobilization during and after
the procedure due to increased operative time, type of
anesthesia, and postoperative pain. It is also possible that
because most of the concomitant operations in our series
were performed during the first study period, several other
confounding factors might have affected the results. In line
with this observation is the result of the multivariate anal-
ysis, where this risk factor did not retain statistical signifi-
cance as an independent variable.
Treatment of incompetent perforators is still a matter of
controversy. The role of incompetent perforators ablation
alone or with GSV treatment awaits results of properly con-
ducted randomized controlled trials.37 Our patient popula-
tion consisted of a large number of elderly individuals (mean
age, 6015 years) with significant comorbidities. At the time
of the study, perforator reflux was investigated and treated
only in a limited number of patients with long-standing non-
healing leg ulcers. Conservative treatment was not successful
in these patients, and they were willing and fit to undergo
surgical perforator interruption. More recently, with the in-
troduction of the RFA Stylet (VNUS Medical Technologies
Inc, San Jose, Calif), which does not require anesthesia or
sedation, we have been able to treat an increasing number of
patients with perforator vein reflux.
After GSV ablation, lower extremity varicose veins of-
ten disappear or visibly regress,10,38 and their elimination
by sclerotherapy or stab avulsion is required in 35% of
patients. In our early experience, elimination of GSV reflux
and phlebectomies of symptomatic or unsightly varicose
veins were performed mostly at the same time. Currently,
most of our patients receive RFA alone as the initial oper-
ative approach to superficial vein reflux. Any significant
varicosities that persist 3 to 6 months are treated by
sclerotherapy or phlebectomies (30%, unpublished data).
This is a retrospective study with certain limitations.
Our protocol included a first follow-up visit 1 week after
the procedure. Patients were asked to return for further
duplex studies, but compliance was 65%. A mean midterm
follow-up of 53 days is reasonable to detect acute/subacute
events but not delayed complications or late results. As
such, the presented data focused on early results rather than
longer-term follow-up.
It is possible that postphlebitic GSVs are at higher risk of
developing DVT after the RFA procedure due to increasedthrombogenicity of the endothelium. By history, patients in
this study who reported an episode of phlebitis had been
treated only with a short course of mild analgesics during the
acute episode. Unfortunately, not enough information on
exact location of previous SVTwas available because this was a
retrospective study and we were unable to determine if it had
involved theGSV. Several risk factors are associatedwith SVT,
and a strong correlation is seenwith certain thrombophilias.39
Testing for hypercoagulable states before endovenous abla-
tion may therefore be indicated in patients with a history of
spontaneous onset of SVT.
One of the main limitations of this study (and of most
reports on post-thrombotic limbs) is that the definition of
post-thrombotic venous stenosis remains obscure, and no
reliable tests are available to confirm the presence of such
lesions. Most thrombosed venous segments recanalize dur-
ing the next 6 to 12 months after an episode of DVT,
leading to chronic luminal changes that may cause partial
obstruction. Unfortunately, the diagnostic evaluation of
secondary chronic venous disease by duplex ultrasound
imaging is not as well defined as for primary venous disease;
thus, there are no reliable criteria to confirm the presence of
such lesions.40 This remains an elusive area in duplex scan-
ning, represents a challenging subject for future studies,
and might have affected our results due to an unavoidable
bias in selecting the limbs that had a previous DVT.
DVT prophylaxis was administered in only in a few
patients with a history of DVT, at the surgeon’s discretion;
these data were not included in the analysis. A recent study
found the use of low-molecular-weight heparin for periop-
erative prophylaxis by a risk-adjusted protocol in patients
undergoing EVLA did not have a significant effect on
thrombotic complications.24 Until further prospective,
randomized studies on DVT prophylaxis in this subset of
patients become available, we do not think the use of
periprocedural anticoagulation is justified because it may be
associated with bleeding complications. Patients with a
history of DVT are not commonly tested for factor V
mutation or other types of hypercoagulability before super-
ficial venous surgery, and it is not routine in our practice. In
the future, however, such information may be useful in
stratifying patients at risk for postprocedural DVT, espe-
cially those with previous thromboembolic events, and
could be the subject for further studies.
CONCLUSIONS
This experience shows that RFA of the GSV can be
safely performed in patients with a history of venous throm-
boembolic events, and it should be offered as an alternative
to surgical procedures for symptomatic superficial vein
reflux. These data call attention to an increased incidence of
AT events when large- diameter GSVs are treated.
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